Searchable abstracts of presentations at key conferences in endocrinology

ea0039oc5.10 | Oral Communications 5 | BSPED2015

Pegvisomant treatment for X-linked acrogigantism syndrome

Coxson Edward , Iacovazzo Donato , Bunce Benjamin , Jose Sian , Ellard Sian , Sampson Julian , Korbonits Marta , Burren Christine

Introduction: Chromosome Xq26.3 microduplications have recently been identified, and explained this 11-year-old girl’s marked tall stature. Her severe phenotype illustrates X-linked acrogigantism (X-LAG) and demonstrates therapeutic benefit from growth hormone receptor blockade.Case: A 5.6-year-old girl presented with growth acceleration from 3 years and appearance of secondary dentition, greasy skin and blackheads from age 4. Past medical and famil...

ea0038p7 | Bone | SFEBES2015

Differential effects of parathyroid hormone on key regulators of osteoblast mineralisation

Houston Dean , Myers Katherine , MacRae Vicky , Millan Jose Luis , Staines Katherine , Farquharson Colin

Intermittent PTH therapy is currently the only anabolic therapy for osteoporosis. As the mineralisation of the extracellular matrix of bone is essential for normal function it is vital that the effects of PTH on key regulators of mineralisation are uncovered. Ablation of Alpl, Phospho1 or Smpd3 results in skeletal hypomineralisation and as such this study examined the effects of bovine (b)PTH 1–34 on their expression. MC3T3 (clone-14) osteoblast-like cells display tempora...

ea0038p76 | Clinical practice/governance and case reports | SFEBES2015

Aromatase inhibitor: potential therapy for obesity related hypogonadotropic hypogonadism and gynaecomastia

Myint Khin Swe , Jose Neetha , Gmoez Javier , Ahluwalia Rupa , Venu Maya

Background: Hypogonadotropic hypogonadism (HH) is commonly associated with morbidly obesity. Gynaecomastia is associated feature of hypogonadism and can be deteriorated by testosterone therapy.History: A 49-year-old gentleman with a BMI of 53.2 kg/m2 was referred for management of obesity. He has two children (age 18 and 22). He had obesity associated comorbidities including obstructive sleep apnoea and impaired fasting glucose. He reported le...

ea0038p334 | Pituitary | SFEBES2015

Clinically non-functioning pituitary macroadenomas: presenting features and outcomes: recent experience at a tertiary centre

Yadagiri Mahender , Vijay Arun , Pritchard Mark , Nayak Ananth , Shaw Simon , Saravanappa Natarajan , Ayuk John , Jose Biju

Introduction: Non-functioning pituitary macroadenoma (NFMA) can cause considerable morbidity due to pituitary dysfunction and pressure effects. We present recent experience in managing cases diagnosed with NFMA at a single tertiary centre between January 2009 and October 2013.Results: Of the 63 patients with NFMA, 28 (44%) were females. Age ranged from 22 to 91 (mean 63). Visual disturbance symptoms (35/63; 57%) were the commonest presentation. Headache ...

ea0037ep457 | Diabetes (complications & therapy) | ECE2015

Clinical experience with lixisenatide in patients with obesity and type 2 diabetes

Tejera Cristina , Delgado Esther , Porca Cristina , Morales Francisco , Bellido Diego , Diaz Jose

Introduction: Agonist receptor-GLP1 (AR-GLP1) had demonstrated its utility in obese patients with diabetes type 2. Since August 2013 we have available in Spain a new AR-GLP1 with prandial action in a single daily dose, lixisenatide. There are different clinical trials that support its efficacy and security but the dates from real clinical practice are scarce.Aim: To analyse the efficacy and security in real clinical practice for the treatment of diabetic...

ea0037ep611 | Obesity and cardiovascular endocrinology | ECE2015

C-reactive protein assay in obese paediatric patients: comparison of two laboratory methods

Alves Jose , Manacas Marta , Faria Carolina , Filipe Lia , Silva Susana , Proenca Helena

Introduction: Obesity as a pro-inflammatory state is associated to increased levels of C-reactive protein (CRP). CPR is considered as a cardiovascular (CV) risk independent marker and is being researched as a predictive atherosclerosis biomarker in obese children. The American Heart Association (AHA) recommends a three classes approach when aiming at CV risk stratification (low <1.0 mg/l; moderate 1.0–3.0 mg/l; and high >3.0 mg/l). These classes were extrapolated ...

ea0037ep893 | Thyroid cancer | ECE2015

Thyroid cancer arises in 5% of patients referred from primary care to a high-resolution thyroid clinic

Doblas Isabel Mancha , Cortes-Salazar Carmen Maria , Fernandez-Garcia Jose Carlos , Tinahones Francisco

Objective: To evaluate the prevalence of thyroid cancer in patients with suspected thyroid nodule referred from primary care.Methods: Retrospective cohort study which included patients with suspected thyroid nodule referred from primary care to a high-resolution thyroid nodule clinic. Demographic and clinical characteristics were collected, all patients underwent thyroid ultrasound and subsequently, a fine-needle aspiration (FNA) was performed if thyroid...

ea0037ep999 | Thyroid (non-cancer) | ECE2015

Descriptive analysis of a series of 1567 thyroidectomies in Castilla La Mancha and its association with thyroid cancer

Castro Enrique , Herranz Sandra , Delgado Manuel , Calderon Dulce , Alfaro Jose Joaquin , Sastre Julia , Del Val Florentino

Introduction: We wanted to analyse the descriptive variables of a series of 1567 thyroidectomy patients between 2010 and 2013 and its association with malignancy in our series.Material and methods: Retrospective, multicentre study done by review of the medical records of 1567 patients who became thyroidectomy between 2010 and 2013 in eight sanitary areas. This is an analysis of clinical and demographic variables.Results: The percen...

ea0035p17 | Adrenal cortex | ECE2014

Female to male gender identity disorder in a patient with non-classical congenital adrenal hyperplasia

Lau Eva , Castedo Jose Luis , Rodrigues Pedro , Figueiredo Zelia , Carvalho Davide

Introduction: Congenital adrenal hyperplasia (CAH) is a prevalent disturb in female to male gender identity disorder (GID). However, psychoendocrinology of GID is not yet fully understood.Case Report: A 22-year-old patient(46, XX), was sent from Psychiatry-Sexology to Endocrinology consultation for GID to start hormonal treatment. Self-awareness as a male began at 12-year-old. Menarche at the age of 13 years. At 14-year-old, it was noticed overgrowth of ...

ea0035p210 | Clinical case reports Pituitary/Adrenal | ECE2014

Diabetes insipidus and hypopituitarism in a patient with idiopathic pulmonary fibrosis

Selfa Silvia Maraver , Garach Araceli Munoz , Cesar Maria Jose Picon , Doblas Isabel Mancha , Madueno Francisco Tinahones

Diabetes insipidus is a disease characterized by the inability to concentrate urine. The common form is central diabetes insipidus (CDI) caused by a lack of AVP after destruction of supraoptic–paraventricular nuclei. Further investigations are needed to establish its cause.: Case reportA 38-year-old woman presented with prompt polyuria–polydipsia. She has been taking contraceptive tablets for 2 years, smoked four to five cigarettes per day....